Work

Secukinumab (Anti‐ IL ‐ 17A Therapeutic Antibody) Improves Clinical Outcome for a Mixed Endotype CRS

Year: 2024

Type: article

Abstract: We identified two CRSwNP patients who had previously failed treatment with an anti-IL-4/IL-13 antibody (dupilumab). Based on their clinical characteristics and blood cytokine levels, we considered them mixed Type II/Type III cases and treated them with an anti-IL-17 antibody (secukinumab). Anti-IL-17 antibody secukinumab was superior in reducing their NPS and SNOT-22 values compared to dupilumab. IL-17 could be a promising target for non-type II and mixed endotype CRS treatment.

Source: Clinical Case Reports

DOI: 10.1002/ccr3.9692

Authors: Mihkel Plaas, Agnieska Brazovskaja, Kai Kisand, Liina Tserel, Pärt Peterson

Institutions: Tartu University Hospital, University of Tartu

Language: English

Topic: Dermatology and Skin Diseases

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,730